FGL1 and neoplasm: While the authors provide mechanistic support for this result, one potential weakness was the lack of assessment for FGL1 acetylation in the in vivo experiments, or in assays of T cell–mediated tumor killing, raising the possibility that antitumor immunity results from some unmeasured effect.